Sandip Kapadia - 26 Jan 2026 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: HRMY
Reported as of: 26 Jan 2026
Net transaction value: -$139,171
SEC form: 4
Accepted by SEC: 28 Jan 2026, 20:19:26 UTC
Prior SEC filing: 26 Jan 2026
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Ulrich, Attorney-in-Fact

Key filing fact

Sandip Kapadia filed Form 4 for Harmony Biosciences Holdings, Inc. (HRMY) on 28 Jan 2026.

Key facts

This page summarizes Sandip Kapadia's Form 4 filing for Harmony Biosciences Holdings, Inc. (HRMY).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jan 2026, 20:19.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: -$139,171.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001677141 Primary reporting owner

Kapadia Sandip

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING
Signature: /s/ Christian Ulrich, Attorney-in-Fact
Signature date: 28 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HRMY transaction

Common Stock

Sale

Transaction value: $139,171
Shares: -3,746
Change %: -13%
Price: $37.15
Shares after: 24,521
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.